While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Every month, roughly 100,000 people buy Zepbound directly from Eli Lilly through its website. "It's about the size of a small city," says David Ricks, Eli Lilly's CEO. That's about 10% of the 1 ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday ... that has helped people with obesity. - Image: UCG / Contributor (Getty Images) A group that ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. (Shelby Knowles/Bloomberg via / Getty Images ...

Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, like Ivim, have stopped taking new patients.